PPA
KRYS icon

Pilgrim Partners Asia’s Krystal Biotech KRYS Stock Holding History

Pilgrim Partners Asia’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-330
Closed -$58.3K – 148
2025
Q3 		$58.3K Buy
+330
New +$49.4K 0.03% 72

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pilgrim Partners Asia's KRYS Position: Q4 2025 in Review

Pilgrim Partners Asia sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 330 shares — an estimated $58.3K sold.

Pilgrim Partners Asia first reported a position in KRYS in Q3 2025 and held it in 1 quarter. The position peaked at $58.3K in Q3 2025. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Pilgrim Partners Asia reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Pilgrim Partners Asia sold 330 Krystal Biotech shares in Q4 2025, an estimated $58.3K.
  • Pilgrim Partners Asia first reported a position in Krystal Biotech in Q3 2025 and held it in 1 quarter.
  • Pilgrim Partners Asia's Krystal Biotech position peaked at $58.3K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Pilgrim Partners Asia's 13F filing for Q4 2025, filed 3 Feb 2026.